Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study

Autor: Kastelein, John J P, Besseling, Joost, Shah, Sukrut, Bergeron, Jean, Langslet, Gisle, Hovingh, G Kees, Al-Saady, Naab, Koeijvoets, Michiel, Hunter, John, Johnson-Levonas, Amy O, Fable, Jennifer, Sapre, Aditi, Mitchel, Yale
Zdroj: In The Lancet 30 May-5 June 2015 385(9983):2153-2161
Databáze: ScienceDirect